tetano
Editor, Senior Moderator
BMJ Open
. 2022 Feb 10;12(2):e053838.
doi: 10.1136/bmjopen-2021-053838.
Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol
Jane Tuckerman[SUP] 1 2 3 [/SUP], Kelly Harper[SUP] 4 5 [/SUP], Thomas R Sullivan[SUP] 6 7 [/SUP], Jennifer Fereday[SUP] 4 [/SUP], Jennifer Couper[SUP] 8 4 5 [/SUP], Nicholas Smith[SUP] 8 4 [/SUP], Andrew Tai[SUP] 4 5 [/SUP], Andrew Kelly[SUP] 8 4 [/SUP], Richard Couper[SUP] 4 [/SUP], Mark Friswell[SUP] 4 [/SUP], Louise Flood[SUP] 9 [/SUP], Margaret Danchin[SUP] 2 3 10 [/SUP], Christopher C Blyth[SUP] 11 12 13 14 [/SUP], Helen Marshall[SUP] 8 4 5 [/SUP]
Affiliations
Abstract
Introduction: Influenza immunisation is a highly cost-effective public health intervention. Despite a comprehensive National Immunisation Program, influenza vaccination in children and adolescents with special risk medical conditions (SRMCs) is suboptimal. Flutext-4U is an innovative, multi-component strategy targeting paediatric hospitals, general practice and parents of children and adolescents with SRMC. The Flutext-4U study aims to assess the impact of Flutext-4U to increase influenza immunisation in children and adolescents with SRMC.
Methods and analysis: This is a randomised controlled trial involving parents of children and adolescents (aged >6 months to <18 years) with SRMC receiving tertiary care at the Women's and Children's Hospital (WCH), Adelaide, South Australia, who are eligible for funded influenza immunisation with a hospital appointment between the start of the seasonal influenza vaccination season and 31 July 2021, their treating general practitioners (GPs), and WCH paediatric specialists.Parents (of children/adolescents with SRMC) are randomised (1:1 ratio) to standard care plus intervention (SMS reminder messages to parents; reminders (written correspondence) for their child's GP from the hospital's Paediatric Outpatients Department) or standard care (hospital vaccine availability, ease of access and reminders for WCH subspecialists) with randomisation stratified by age-group (<5, 5-14, >14 to <18 years).The primary outcome is influenza vaccination, as confirmed by the Australian Immunisation Register.The proportion vaccinated (primary outcome) will be compared between randomised groups using logistic regression, with adjustment made for age group at randomisation. The effect of treatment will be described using an OR with a 95% CI.
Ethics and dissemination: The protocol and all study materials have been reviewed and approved by the Women's and Children's Health Network Human Research Ethics Committee (HREC/20/WCHN/5). Results will be disseminated via peer-reviewed publication and at scientific meetings, professional and public forums.
Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12621000463875).
Keywords: paediatric infectious disease & immunisation; preventive medicine; protocols & guidelines; public health.
. 2022 Feb 10;12(2):e053838.
doi: 10.1136/bmjopen-2021-053838.
Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol
Jane Tuckerman[SUP] 1 2 3 [/SUP], Kelly Harper[SUP] 4 5 [/SUP], Thomas R Sullivan[SUP] 6 7 [/SUP], Jennifer Fereday[SUP] 4 [/SUP], Jennifer Couper[SUP] 8 4 5 [/SUP], Nicholas Smith[SUP] 8 4 [/SUP], Andrew Tai[SUP] 4 5 [/SUP], Andrew Kelly[SUP] 8 4 [/SUP], Richard Couper[SUP] 4 [/SUP], Mark Friswell[SUP] 4 [/SUP], Louise Flood[SUP] 9 [/SUP], Margaret Danchin[SUP] 2 3 10 [/SUP], Christopher C Blyth[SUP] 11 12 13 14 [/SUP], Helen Marshall[SUP] 8 4 5 [/SUP]
Affiliations
- PMID: 35144952
- DOI: 10.1136/bmjopen-2021-053838
Abstract
Introduction: Influenza immunisation is a highly cost-effective public health intervention. Despite a comprehensive National Immunisation Program, influenza vaccination in children and adolescents with special risk medical conditions (SRMCs) is suboptimal. Flutext-4U is an innovative, multi-component strategy targeting paediatric hospitals, general practice and parents of children and adolescents with SRMC. The Flutext-4U study aims to assess the impact of Flutext-4U to increase influenza immunisation in children and adolescents with SRMC.
Methods and analysis: This is a randomised controlled trial involving parents of children and adolescents (aged >6 months to <18 years) with SRMC receiving tertiary care at the Women's and Children's Hospital (WCH), Adelaide, South Australia, who are eligible for funded influenza immunisation with a hospital appointment between the start of the seasonal influenza vaccination season and 31 July 2021, their treating general practitioners (GPs), and WCH paediatric specialists.Parents (of children/adolescents with SRMC) are randomised (1:1 ratio) to standard care plus intervention (SMS reminder messages to parents; reminders (written correspondence) for their child's GP from the hospital's Paediatric Outpatients Department) or standard care (hospital vaccine availability, ease of access and reminders for WCH subspecialists) with randomisation stratified by age-group (<5, 5-14, >14 to <18 years).The primary outcome is influenza vaccination, as confirmed by the Australian Immunisation Register.The proportion vaccinated (primary outcome) will be compared between randomised groups using logistic regression, with adjustment made for age group at randomisation. The effect of treatment will be described using an OR with a 95% CI.
Ethics and dissemination: The protocol and all study materials have been reviewed and approved by the Women's and Children's Health Network Human Research Ethics Committee (HREC/20/WCHN/5). Results will be disseminated via peer-reviewed publication and at scientific meetings, professional and public forums.
Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12621000463875).
Keywords: paediatric infectious disease & immunisation; preventive medicine; protocols & guidelines; public health.